Literature DB >> 15613457

Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes.

M Onda1, M Emi, A Yoshida, S Miyamoto, J Akaishi, S Asaka, K Mizutani, K Shimizu, M Nagahama, K Ito, T Tanaka, T Tsunoda.   

Abstract

Little is known about the genetic mechanisms of anaplastic thyroid cancer (ATC). This is the most virulent of all human malignancies, and it is believed to result from transformation of differentiated thyroid cancers. To identify a set of genes involved in the development of ATC, we investigated expression profiles of 11 cell lines derived from ATC using a cDNA microarray representing 25 344 genes. Semi-quantitative RT-PCR experiments carried out for some genes that had shown altered expression on the microarray verified frequent over-expression of destrin, HSPA8, stathmin, LDH-A, ATP5A1, PSMB6, B23, HDP-1 and LDH-B, and frequent under-expression of thyroglobulin, PBP and c-FES/FPS genes among the cell lines and also among ten primary ATCs. In addition to mRNA expression studies, up-regulation of GDI2, destrin and stathmin were confirmed with immunohistochemical analysis. The extensive list of genes identified provides valuable information towards understanding the development of ATC, and provides a source of possible biomarkers for diagnosis and/or molecular targets for the development of novel drugs to treat ATC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15613457     DOI: 10.1677/erc.1.00818

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  22 in total

1.  Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.

Authors:  Paul Weinberger; Sithara Raju Ponny; Hongyan Xu; Shan Bai; Robert Smallridge; John Copland; Ashok Sharma
Journal:  Thyroid       Date:  2016-12-15       Impact factor: 6.568

Review 2.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

3.  Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.

Authors:  J Akaishi; M Onda; J Okamoto; S Miyamoto; M Nagahama; K Ito; A Yoshida; K Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

Review 4.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

5.  Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.

Authors:  Peter M Sadow; Kandelaria M Rumilla; Lori A Erickson; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 6.  Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

Authors:  P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré
Journal:  Clin Transl Oncol       Date:  2016-04-05       Impact factor: 3.405

7.  Decreased expression of haemoglobin beta (HBB) gene in anaplastic thyroid cancer and recovery of its expression inhibits cell growth.

Authors:  M Onda; J Akaishi; S Asaka; J Okamoto; S Miyamoto; K Mizutani; A Yoshida; K Ito; M Emi
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

8.  Recent progress of genome study for anaplastic thyroid cancer.

Authors:  Jieun Lee; Jung-Ah Hwang; Eun Kyung Lee
Journal:  Genomics Inform       Date:  2013-06-30

9.  Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.

Authors:  Junko Akaishi; Masamitsu Onda; Junichi Okamoto; Shizuyo Miyamoto; Mitsuji Nagahama; Kouichi Ito; Akira Yoshida; Kazuo Shimizu
Journal:  BMC Cancer       Date:  2006-11-01       Impact factor: 4.430

10.  An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells.

Authors:  Soma Mandal; James R Davie
Journal:  BMC Cancer       Date:  2007-09-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.